Table 1.
Baseline patient demographics and disease characteristics
| Characteristic | UPA 15 mg + TCS, N = 91 | UPA 30 mg + TCS, N = 91 | Placebo + TCS, N = 90 |
|---|---|---|---|
| Female, n (%) | 23 (25.3) | 22 (24.2) | 16 (17.8) |
| Age, years, mean (SD) | 35.9 (13.2) | 34.7 (12.7) | 36.3 (12.6) |
| Age group, n (%) | |||
| < 18 years | 8 (8.8) | 8 (8.8) | 9 (10.0) |
| 18–75 years | 83 (91.2) | 83 (91.2) | 81 (90.0) |
| Weight, kg, mean (SD) | 65.1 (14.2) | 66.2 (14.4) | 67.6 (12.8) |
| Affected BSA, %, mean (SD) | 61.7 (23.7) | 66.7 (21.2) | 62.0 (20.5) |
| Disease duration since diagnosis, years, mean (SD) | 23.0 (14.3) | 20.7 (14.1) | 24.7 (14.4) |
| hsCRP, mg/L, mean (SD) | 2.3 (3.8) | 3.9 (8.8) | 3.1 (6.4) |
| vIGA-AD, n (%) | |||
| Moderate (score of < 4) | 47 (51.6) | 48 (52.7) | 47 (52.2) |
| Severe (score of 4) | 44 (48.4) | 43 (47.3) | 43 (47.8) |
| EASI, mean (SD) | 34.2 (14.1) | 36.1 (14.4) | 34.4 (13.0) |
| Worst Pruritus NRS score, mean (SD) | 6.7 (1.4) | 7.0 (1.4) | 6.8 (1.3) |
BSA body surface area, EASI Eczema Area and Severity Index, hsCRP high-sensitivity C-reactive protein, NRS numerical rating scale, TCS topical corticosteroids, UPA upadacitinib, vIGA-AD validated Investigator Global Assessment for Atopic Dermatitis